The authors concluded that the therapeutic inhibition of miR-23a might be a strategy to rescue PGC-1α activity and ameliorate skeletal muscle mitochondrial function in ALS [28]. The gene discussed is PPARGC1A; the disease is amyotrophic lateral sclerosis.